These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Targeted therapies for hepatocellular carcinoma.
    Author: Skelton MR, O'Neil B.
    Journal: Clin Adv Hematol Oncol; 2008 Mar; 6(3):209-18. PubMed ID: 18391920.
    Abstract:
    Hepatocellular carcinoma (HCC) remains a highly lethal disease that is resistant to traditional cytotoxic chemotherapy. The last 30 years of chemotherapy clinical trials for advanced HCC have repeatedly failed to demonstrate any survival benefit for a long list of drugs. However a survival advantage was recently established for sorafenib, instituting a new standard of care for unresectable HCC. Here we review recent and ongoing studies of new therapeutic agents for HCC, including the small-molecule tyrosine kinase inhibitors, monoclonal antibodies, and combinations of these drugs.
    [Abstract] [Full Text] [Related] [New Search]